Hosted on MSN1mon
GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE ... is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing ...
Pharmabiz29d
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
GSK plc announced that the European Medicines ... multi-centre phase III clinical trials. The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...
pharmaphorum5d
GSK’s Relvar Ellipta comes out on top in real world study
and 44% reduction in a 52 week trial, and the FDA is expected to approve this combination later this year. Regulators have started reviews of GSK's depemokimab, aiming to become the first drug ...
Investing1mon
Depemokimab reviewed for asthma and CRSwNP in Asia
LONDON - GSK plc (LSE/NYSE ... on the positive outcomes of the SWIFT and ANCHOR phase III clinical trials. In the SWIFT trials, depemokimab demonstrated a significant reduction in exacerbation ...
The Globe and Mail22d
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical ... Severe Asthma Pipeline Outlook GSK 3511294, also known as depemokimab, is a long acting, interleukin ...
pharmaphorum1d
GSK’s Relvar Ellipta comes out on top in real world study
and 44% reduction in a 52 week trial, and the FDA is expected to approve this combination later this year. Regulators have started reviews of GSK's depemokimab, aiming to become the first drug ...